Cosmetics Direct Gets Two Portal “Fillers” – Discontinuation and Relisting Features Added
Client Alert | 1 min read | 08.06.24
On July 29, 2024, FDA announced that it added two new features to Cosmetics Direct, the electronic submission portal used for the facility registration and product listing requirements now in effect under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). The portal now allows responsible persons to “discontinue” and “relist” cosmetic products.
Here’s how it works: rather than deleting a cosmetic product that is no longer on the market, the responsible person (i.e., the manufacturer, packer or distributor whose name appears on the product’s label) can now select “discontinue.” The practical effect of selecting “discontinue” is that the product’s information will remain in the Structure Product Labeling file on Cosmetics Direct, rather than being permanently deleted. The corresponding “relisting” feature enables the responsible person to relist any discontinued cosmetics that are being put back on to the market. Together, these new features provide a more efficient experience for the responsible person, who would otherwise have to start over and list a new product if and when a discontinued cosmetic is being put back on the market—e.g., after a temporary decision to stop sales.
To view more details about these new features, as well as instructions on how to use the Cosmetics Direct portal, FDA published an updated User’s Guide.
These changes come approximately one month after FDA began enforcing MoCRA’s product listing and facility registration requirements on July 1, 2024, and show FDA is taking steps to make compliance with MoCRA more user friendly. Responsible persons should review and monitor FDA’s Cosmetics Direct webpage to keep abreast of the latest resources for registration and listing of cosmetic products. We will continue to monitor and report on the latest developments as well.
Insights
Client Alert | 10 min read | 03.27.25
FinCEN Axes Corporate Transparency Act’s Reporting Obligations for U.S. Companies and U.S. Persons
Since December of last year, the status of the CTA has been in a state of perpetual flux, following a dizzying series of federal court rulings and FinCEN announcements. On February 28, 2025, we reported that FinCEN paused enforcement actions for entities required to report under the CTA’s Beneficial Ownership Information Reporting Rule (BOI Rule) until FinCEN issued an interim final rule providing new guidance regarding the BOI Rule’s requirements and associated deadlines. Then, on March 2, 2025, Treasury went a step further, indicating that it would altogether cease enforcement against U.S. citizens and domestic reporting companies for violations of the BOI Rule, explaining that it would instead issue proposed rulemaking to narrow the scope of the BOI Rule to “foreign reporting companies” only and set new reporting deadlines.
Client Alert | 3 min read | 03.27.25
Client Alert | 3 min read | 03.27.25
MoCRA Under the Trump Era: A Look at FDA's Monitoring and Enforcement Two Months In
Client Alert | 4 min read | 03.27.25